Ambalal Sarabhai [AMBALALSA] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Ambalal Sarabhai Enterprises Ltd. wins in 15 metrics, Sun Pharma Advanced Research Company Ltd. wins in 3 metrics, with 0 ties. Ambalal Sarabhai Enterprises Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Ambalal Sarabhai Enterprises Ltd. | Sun Pharma Advanced Research Company Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 23.36 | -13.65 | Ambalal Sarabhai Enterprises Ltd. |
| Price-to-Book Ratio | 1.72 | -13.55 | Ambalal Sarabhai Enterprises Ltd. |
| Debt-to-Equity Ratio | 31.59 | -1.21 | Ambalal Sarabhai Enterprises Ltd. |
| PEG Ratio | 0.62 | -11.15 | Ambalal Sarabhai Enterprises Ltd. |
| EV/EBITDA | 12.52 | -22.27 | Ambalal Sarabhai Enterprises Ltd. |
| Profit Margin (TTM) | 5.16% | -53.22% | Ambalal Sarabhai Enterprises Ltd. |
| Operating Margin (TTM) | 10.95% | -700.71% | Ambalal Sarabhai Enterprises Ltd. |
| EBITDA Margin (TTM) | 10.95% | N/A | N/A |
| Return on Equity | 3.52% | 157.88% | Sun Pharma Advanced Research Company Ltd. |
| Return on Assets (TTM) | 1.83% | -102.08% | Ambalal Sarabhai Enterprises Ltd. |
| Free Cash Flow (TTM) | $-203.34M | $-3.71B | Ambalal Sarabhai Enterprises Ltd. |
| 1-Year Return | -5.76% | 14.56% | Sun Pharma Advanced Research Company Ltd. |
| Price-to-Sales Ratio (TTM) | 1.20 | 87.98 | Ambalal Sarabhai Enterprises Ltd. |
| Enterprise Value | $2.77B | $50.87B | Sun Pharma Advanced Research Company Ltd. |
| EV/Revenue Ratio | 1.36 | 95.73 | Ambalal Sarabhai Enterprises Ltd. |
| Gross Profit Margin (TTM) | 41.99% | -59.53% | Ambalal Sarabhai Enterprises Ltd. |
| Revenue per Share (TTM) | $26 | $2 | Ambalal Sarabhai Enterprises Ltd. |
| Earnings per Share (Diluted) | $1.36 | $-8.25 | Ambalal Sarabhai Enterprises Ltd. |
| Beta (Stock Volatility) | -0.14 | 0.19 | Ambalal Sarabhai Enterprises Ltd. |
Ambalal Sarabhai Enterprises Ltd. vs Sun Pharma Advanced Research Company Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ambalal Sarabhai Enterprises Ltd. | -3.15% | 14.81% | 14.78% | 47.15% | 31.73% | 28.76% |
| Sun Pharma Advanced Research Company Ltd. | 2.09% | -13.30% | 46.20% | 62.20% | 26.84% | 51.26% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ambalal Sarabhai Enterprises Ltd. | -5.76% | 68.27% | -36.94% | 323.87% | 381.00% | 225.94% |
| Sun Pharma Advanced Research Company Ltd. | 14.56% | 13.10% | -5.14% | -23.02% | 148.11% | -27.03% |
Performance & Financial Health Analysis: Ambalal Sarabhai Enterprises Ltd. vs Sun Pharma Advanced Research Company Ltd.
| Metric | AMBALALSA | SPARC |
|---|---|---|
| Market Information | ||
| Market Cap | ₹2.43B | ₹46.75B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 84,061 | 2,401,062 |
| 90 Day Avg. Volume | 120,526 | 2,083,443 |
| Last Close | ₹36.03 | ₹208.50 |
| 52 Week Range | ₹23.12 - ₹38.85 | ₹108.00 - ₹248.75 |
| % from 52W High | -7.26% | -16.18% |
| All-Time High | ₹77.70 (Jul 08, 2024) | ₹875.00 (Apr 24, 2006) |
| % from All-Time High | -53.63% | -76.17% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.13% | -0.43% |
| Quarterly Earnings Growth | 0.37% | -0.43% |
| Financial Health | ||
| Profit Margin (TTM) | 0.05% | -0.53% |
| Operating Margin (TTM) | 0.11% | -7.01% |
| Return on Equity (TTM) | 0.04% | 1.58% |
| Debt to Equity (MRQ) | 31.59 | -1.21 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹18.44 | ₹-10.63 |
| Cash per Share (MRQ) | ₹1.73 | ₹0.03 |
| Operating Cash Flow (TTM) | ₹-299,709,000 | ₹-3,484,287,000 |
| Levered Free Cash Flow (TTM) | ₹49.31M | ₹-3,425,094,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Ambalal Sarabhai Enterprises Ltd. vs Sun Pharma Advanced Research Company Ltd.
| Metric | AMBALALSA (Apr 24, 2026) | SPARC (Apr 22, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 23.36 | -13.65 |
| Forward P/E | N/A | 2.60 |
| PEG Ratio | 0.62 | -11.15 |
| Price to Sales (TTM) | 1.20 | 87.98 |
| Price to Book (MRQ) | 1.72 | -13.55 |
| Market Capitalization | ||
| Market Capitalization | ₹2.43B | ₹46.75B |
| Enterprise Value | ₹2.77B | ₹50.87B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.36 | 95.73 |
| Enterprise to EBITDA | 12.52 | -22.27 |
| Risk & Other Metrics | ||
| Beta | -0.14 | 0.19 |
| Book Value per Share (MRQ) | ₹18.44 | ₹-10.63 |
Financial Statements Comparison: Ambalal Sarabhai Enterprises Ltd. vs Sun Pharma Advanced Research Company Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | AMBALALSA (2025) | SPARC (2025) |
|---|---|---|
| Revenue/Sales | 1.95B | 717.66M |
| Cost of Goods Sold | 1.23B | 1.10B |
| COGS % of Revenue | 62.9% | 153.2% |
| Gross Profit | 723.71M | -381.94M |
| Gross Margin | 37.1% | -53.2% |
| Research & Development | 165,000 | N/A |
| Operating Income (EBIT) | 92.36M | -3.34B |
| Operating Margin | 4.7% | -465.5% |
| EBITDA | 205.00M | -3.23B |
| EBITDA Margin | 10.5% | -450.0% |
| Pre-Tax Income | 48.34M | -3.43B |
| Pre-Tax Income % of Revenue | 2.5% | -477.6% |
| Income Tax | -981,000 | -2.72M |
| Income Tax % of Revenue | -0.1% | -0.4% |
| Net Income (Profit) | 49.32M | -3.43B |
| Profit Margin | 2.5% | -477.3% |
Balance Sheet & Liquidity Metrics
| Metric | AMBALALSA (2025) | SPARC (2025) |
|---|---|---|
| Cash & Equivalents | 48.95M | 19.64M |
| Total Current Assets | 1.18B | 261.97M |
| Total Current Assets % of Revenue | 60.7% | 36.5% |
| Total Current Liabilities | 1.20B | 3.74B |
| Total Current Liabilities % of Revenue | 61.6% | 521.5% |
| Long-Term Debt | 90.15M | 1.07B |
| Long-Term Debt % of Revenue | 4.6% | 149.0% |
| Total Shareholders Equity | 1.40B | -2.17B |
| Retained Earnings | -28.33M | -23.22B |
| Retained Earnings % of Revenue | -1.5% | -3,235.0% |
| Property, Plant & Equipment | 50.63M | 178.02M |
Cash Flow Statement Comparison
| Metric | AMBALALSA (2025) | SPARC (2025) |
|---|---|---|
| Operating Cash Flow | -299.71M | -3.48B |
| Operating Cash Flow % of Revenue | -15.3% | -485.5% |
| Capital Expenditures | -25.45M | -97.45M |
| Free Cash Flow | -203.34M | -3.71B |
| FCF Margin | -10.4% | -516.4% |
| Debt Repayment | N/A | -3.69B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AMBALALSA | SPARC |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 76.63M | 324.52M |
| Float Shares | 46.90M | 91.32M |
| % Held by Insiders | 34.99% | 72.96% |
| % Held by Institutions | 0.00% | 2.56% |
| % Held by Public | 65.01% | 24.48% |
Dividend Analysis & Yield Comparison: Ambalal Sarabhai Enterprises Ltd. vs Sun Pharma Advanced Research Company Ltd.
| Metric | AMBALALSA | SPARC |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |